Peptide Sequences for Chlamydophila pneumoniae Vaccine and Serological Diagnosis


CDC researchers have isolated select Chlamydophila pneumoniae peptide epitopes for development of vaccines and diagnostic assays. Currently, C. pneumoniae infection of humans has been linked to a wide variety of acute and chronic diseases, such as asthma, endocarditis, atherosclerotic vascular disease, chronic obstructive pulmonary disease, sarcoidosis, reactive arthritis and multiple sclerosis. There is presently no available peptide vaccine for the pathogen and reliable and accurate diagnostic methods are limited.

This technology encompasses polypeptide sequences that are specifically recognized by anti-C. pneumoniae antibodies. These antigens may be useful for improving diagnostic methods by reducing the variability and high backgrounds found with methods that rely on whole organisms for detection. Further, this technology may also be useful for production of peptide or DNA-based vaccines directed against C. pneumoniae.

Potential Commercial Applications: Competitive Advantages:
  • C. pneumoniae vaccine and/or therapeutic developments
  • Public health surveillance programs
  • Clinical serological diagnostics development
 
  • No peptide vaccine for C. pneumoniae is presently available
  • Present assays for the diagnosis of C. pneumoniae infections are laborious and limited in efficacy


Development Stage:
In vitro data available

Inventors:

Eric Marston (CDC)  ➽ more inventions...

Jacquelyn Sampson (CDC)  ➽ more inventions...

George Carlone (CDC)  ➽ more inventions...

Edwin Ades (CDC)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 7,223,836 issued 2007-05-29
US Application No. 60/296,496
US Application No. 10/479,503

Publications:
Marston EL, et al. PMID 11874892

Licensing Contact:
Karen Surabian, J.D., M.B.A.
Email: karen.surabian@nih.gov
Phone: 301-594-9719

OTT Reference No: E-235-2013/0
Updated: Feb 7, 2014